TES 1025
Alternative Names: ACMSD inhibitor - TES pharma; TES-1025Latest Information Update: 03 Mar 2023
Price :
$50 *
At a glance
- Originator Tes Pharma
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action Aminocarboxymuconate semialdehyde decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury; Inflammation; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 18 Jan 2023 Preclinical trials in Acute kidney injury in Italy (TES pharma pipeline, January 2023)
- 18 Jan 2023 Preclinical trials in Inflammation in Italy (TES pharma pipeline, January 2023)
- 18 Jan 2023 Preclinical trials in Non-alcoholic fatty liver disease in Italy(TES pharma pipeline, January 2023)